FutureCeuticals Settles IP Dispute, Aura to Sell CognatiQ
Image
Momence, Illinois – September 08, 2026 -- FutureCeuticals, Inc. and Aura Scientific have settled a patent and trademark dispute over Aura's cognitive-health ingredient "NeuroRush," ending the product and replacing it with a new distribution partnership for FutureCeuticals' whole coffee cherry extract, sold as "CognatiQ" and "NeuroFactor."
Settlement terminates NeuroRush, validates FutureCeuticals' IP portfolio
The resolution confirms the validity of FutureCeuticals' intellectual property in the cognitive health ingredient category, according to J. Randal Wexler, the company's Vice President and General Counsel. Aura's NeuroRush ingredient will be discontinued as part of the agreement.